eicosapentaenoic acid + statin

This refers to the **combination of eicosapentaenoic acid (EPA)**, an omega-3 fatty acid, and a **statin** (a member of the hydroxymethylglutaryl-CoA reductase inhibitor drug class). The combination is utilized for cardiovascular risk reduction—primarily in patients with dyslipidemia and/or established coronary artery disease—by leveraging the lipid-modulating effects of both agents. EPA acts mainly by reducing plasma triglyceride levels and exerting anti-inflammatory and plaque-stabilizing effects, while statins lower LDL cholesterol by inhibiting cholesterol biosynthesis. This dual approach provides additional reduction in major adverse cardiovascular events (MACE) and myocardial infarction incidence compared to statin monotherapy, and may offer plaque stabilizing benefits through arterial inflammation suppression[1][2][3].